FOSTEMSAVIR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H26N7O8P
Molecular Weight	583.4908
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cc1ncn(-c2c3c(c(cn3COP(=O)(O)O)C(=O)C(=O)N4CCN(CC4)C(=O)c5ccccc5)c(cn2)OC)n1

InChI

InChIKey=SWMDAPWAQQTBOG-UHFFFAOYSA-N

InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)

HIDE SMILES / InChI

Description
Sources: https://aidsinfo.nih.gov/drugs/508/fostemsavir/0/patient | https://www.hiv.uw.edu/page/treatment/drugs/fostemsavir | https://www.ncbi.nlm.nih.gov/pubmed/27922453

Fostemsavir (BMS-663068) is an investigational attachment inhibitor with a unique mechanism of action. It is a prodrug of temsavir, which binds to HIV envelope glycoprotein 120 (gp120), thereby preventing viral attachment to the host CD4 cell surface receptor. In the absence of effective binding of HIV gp120 with the host CD4 receptor, HIV does not enter the host cell. Because fostemsavir has a novel mechanism of action, the drug should have full activity against HIV strains that have developed resistance to other classes of antiretroviral medications. In a phase 2b study of treatment-experienced individuals, fostemsavir appeared to be well tolerated. Phase 3 studies are ongoing.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus 1 32 Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22547625	Inhibitor 7701	HIV-1 infection

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 140 Sources: http://adisinsight.springer.com/drugs/800031504 https://clinicaltrials.gov/ct2/show/NCT02362503	Primary	Human immunodeficiency virus 1	Phase III 650

C_max

Value	Dose	Co-administered	Analyte	Population
1770 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: other antiretroviral drugs	other antiretroviral drugs	TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.39 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22896665/	1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED
2.55 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg single, oral dose: 1200 mg route of administration: oral experiment type: single co-administered:		TEMSAVIR plasma	Homo sapiens
3.18 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
3.38999999999999 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
3.61 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
12900 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: other antiretroviral drugs	other antiretroviral drugs	TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
42.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22896665/	1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED
13.8 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg single, oral dose: 1200 mg route of administration: oral experiment type: single co-administered:		TEMSAVIR plasma	Homo sapiens
19.5 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
22.5 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens
42.6 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01009814	1200 mg 1 times / 12 hours multiple, oral dose: 1200 mg route of administration: oral experiment type: multiple co-administered:		TEMSAVIR plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
11 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
26.9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		TEMSAVIR plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	unhealthy, 17-43 years Health Status: unhealthy Age Group: 17-43 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	Disc. AE: Immune reconstitution inflammatory syndrome... Other AEs: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Immune reconstitution inflammatory syndrome (grade 3, 3%) Other AEs: Nausea (grade 1-4, 10%) Diarrhea (grade 1-4, 4%) Headache (grade 1-4, 4%) Abdominal pain (grade 1-4, 3%) Dyspepsia (grade 1-4, 3%) Fatigue (grade 1-4, 3%) Rash (grade 1-4, 3%) Sleep disturbance (grade 1-4, 3%) Immune reconstitution inflammatory syndrome (grade 1-4, 2%) Somnolence (grade 1-4, 2%) Vomiting (grade 1-4, 2%) ALT increased (grade 3-4, 5%) AST increased (grade 3-4, 4%) Direct bilirubin increased (grade 3, 7%) Bilirubin increased (grade 3-4, 3%) Creatinine increased (grade 3-4, 19%) Creatine kinase increased (grade 3-4, 2%) Hemoglobin decreased (grade 3-4, 6%) Hyperglycemia (grade 3-4, 4%) Lipase increased (grade 3-4, 5%) Neutrophils reduced (grade 3-4, 4%) Blood triglycerides increased (grade 3-4, 5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years Health Status: healthy Age Group: 18-49 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	Other AEs: Scleral icterus, Abdominal pain... Other AEs: Scleral icterus (27.8%) Abdominal pain (11.1%) Headache (13.9%) Dizziness (5.6%) Nausea (8.3%) Musculoskeletal chest pain (2.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years Health Status: healthy Age Group: 18-49 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	Other AEs: Headache... Other AEs: Headache (5.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	healthy, 18-49 years Health Status: healthy Age Group: 18-49 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/	Other AEs: Scleral icterus, Abdominal pain... Other AEs: Scleral icterus (5.6%) Abdominal pain (5.6%) Nausea (5.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/25870057/
1050 mg 2 times / day steady, oral Studied dose Dose: 1050 mg, 2 times / day Route: oral Route: steady Dose: 1050 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Other AEs: Headache... Other AEs: Headache (grade 1, 14%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
1200 mg 1 times / day steady, oral Studied dose Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Disc. AE: Disseminated tuberculosis, Back pain... AEs leading to discontinuation/dose reduction: Disseminated tuberculosis (2%) Back pain (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
400 mg 2 times / day steady, oral Studied dose Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Disc. AE: Ischaemia... AEs leading to discontinuation/dose reduction: Ischaemia (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
800 mg 2 times / day steady, oral Studied dose Dose: 800 mg, 2 times / day Route: oral Route: steady Dose: 800 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	unhealthy, adults Health Status: unhealthy Age Group: adults Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/	Disc. AE: Bone tuberculosis, Acute renal failure... AEs leading to discontinuation/dose reduction: Bone tuberculosis (2%) Acute renal failure (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26423650/
2400 mg 2 times / day steady, oral Highest studied dose Dose: 2400 mg, 2 times / day Route: oral Route: steady Dose: 2400 mg, 2 times / day Sources: https://www.fda.gov/media/140641/download	healthy Health Status: healthy Sources: https://www.fda.gov/media/140641/download	Other AEs: QT interval prolonged... Other AEs: QT interval prolonged Sources: https://www.fda.gov/media/140641/download

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1172 inducer 657	substrate 865 inhibitor 1318	substrate 1038 inhibitor 1421	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 698 OATP1B3 613 CYP 97 UGT 29 BCRP 574 MATE2 258 CYP1A2 1268 CYP2B6 679 CYP2C8 761 CYP2C19 1215 CYP2A6 594 UGT1A1 174 UGT1A4 67 UGT1A9 102 UGT1A6 94 UGT2B7 130 P-gp 1089 OAT1 547 OAT3 570 MATE1 290 MRP2 341 NTCP 31 OCT2 582 BSEP 363 OCT1 473	CYP3A 154 P-gp 1223 BCRP 461 esterase 63 UGT 160 CYP1A1 302 CYP1A2 892 CYP2A6 452 CYP1B1 82 CYP2B6 575 CYP2C8 586 CYP2C19 830 FMO3 49 CYP4A11 90 CYP2E1 567 CYP3A5 346	CYP1A2 618 CYP2B6 486

Drug as perpetrator

Target	Modality	Activity	Metabolite
OAT1 551	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 182	no [IC50 110 uM]	temsavir 4
OCT1 488	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 184	no [IC50 32.8 uM]	temsavir 4
UGT1A6 126	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >10 uM]	temsavir 4
UGT1A9 107	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >10 uM]	temsavir 4
UGT2B7 138	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 177	no [IC50 >10 uM]
UGT2B7 138	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 177	no [IC50 >10 uM]	temsavir 4
OCT2 583	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 184	no [IC50 >100 uM]	temsavir 4
UGT1A1 219	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >100 uM]
UGT1A1 219	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >100 uM]	temsavir 4
UGT1A4 70	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >100 uM]
UGT1A4 70	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >100 uM]	temsavir 4
UGT1A6 126	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >100 uM]
UGT1A9 107	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 176	no [IC50 >100 uM]
BCRP 639	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 181	no [IC50 >250 uM]
P-gp 1255	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 181	no [IC50 >250 uM]
CYP1A2 1406	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174	no [IC50 >40 uM]	temsavir 4
CYP2A6 625	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175	no [IC50 >40 uM]	temsavir 4
CYP2B6 845	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174	no [IC50 >40 uM]	temsavir 4
CYP2C19 1277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175	no [IC50 >40 uM]	temsavir 4
CYP2C8 810	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174	no [IC50 >40 uM]	temsavir 4
CYP2C9 1362	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 174	no [IC50 >40 uM]	temsavir 4
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175	no [IC50 >40 uM]	temsavir 4
CYP3A4 1462	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 175	no [IC50 >40 uM]	temsavir 4
BSEP 364	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 184	no [IC50 >50 uM]	temsavir 4
MRP2 421	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 183	no [IC50 >50 uM]	temsavir 4
NTCP 32	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 183	no [IC50 >50 uM]	temsavir 4
OAT3 572	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 182	no [IC50 >50 uM]	temsavir 4
P-gp 1255	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 181	no [Inhibition 25 uM]	temsavir 4
CYP 131	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36	no	temsavir 4
CYP1A2 1406	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 177	no	temsavir 4
CYP2B6 845	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 178	no	temsavir 4
CYP3A4 1462	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 178	no	temsavir 4
UGT 49	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36	no	temsavir 4
MATE2 258	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 183	yes [IC50 12.2 uM]	temsavir 4
MATE1 291	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 182	yes [IC50 18.5 uM]	temsavir 4
BCRP 639	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 114	yes	temsavir 4
OATP1B1 713	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 114, 180	yes	temsavir 4
OATP1B3 622	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 36, 114, 181	yes	temsavir 4

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
UGT 160	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35	minor	temsavir 4
CYP1A1 302	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP1A2 892	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP1B1 82	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP2A6 452	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP2B6 575	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP2C19 830	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP2C8 586	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP2C9 865	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP2D6 1038	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP2E1 567	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP3A5 346	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
CYP4A11 90	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
FMO3 49	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 173	no	temsavir 4
BCRP 461	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 179	yes	temsavir 4
P-gp 1223	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 179	yes	temsavir 4
esterase 63	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35	yes	temsavir 4
CYP3A 154	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 111, 112, 113	yes	temsavir 4	yes (co-administration study) Comment: coadministration of fostemsavir with rifampin significantly decreases temsavir plasma concentrations, reduced temsavir AUC by 80%; coadministration of fostemsavir with drugs that are strong CYP3A inducers result in decreased concentrations of temsavir. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 35, 111, 112, 113

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf Page: 69		temsavir 4

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00GUIL
1PlusChem LLC	1P00GUIM
AK Scientific	3038AH
AK Scientific	3502AH
APExBIO	A3254
AbovChem LLC	HY-15440A
AbovChem LLC	HY-15440B
Angene	AGN-PC-0WCXR0
BLDpharm	BD630927
Chem Scene	CS-1059
Chem Scene	CS-1060
ChemShuttle	139027
Compound Cloud	11319217
Compound Cloud	46892186
Excenen	EX-A1973
Hairui	FOXF012
Hangzhou APIChem Technology	AC-30663
Hangzhou Yuhao Chemical Technology	YH65070
Lan Pharmatech	LQT-B02863
MedChem Express	HY-15440A
MedChem Express	HY-15440B
MolPort	MolPort-038-387-826
MolPort	MolPort-039-139-439
Molnova	M19191
MuseChem	I006855
ShangHai Biochempartner	BCP13226
Synthonix	13387
Synthonix	1788
TargetMol	T3523
ZINC	ZINC000014210883	http://zinc15.docking.org/substances/ZINC000014210883
eMolecules	44811300
eMolecules	44811308
eNovation Chemicals	D501819
mcule	MCULE-3512432527

PubMed

Title	Date	PubMed
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.	2017	27922453
[What can new substances offer?]	2017 Jun	28597267

Patents

Sample Use Guides

In Vivo Use Guide

A phase 2b trial enrolled treatment-experienced adults with HIV infection and randomized study subjects to one of four doses of fostemsavir (400 mg twice daily, 800 mg twice daily, 600 mg once daily, or 1200 mg once daily).

Route of Administration: Oral

In Vitro Use Guide

BMS-626529 (an active moiety of BMS-663068) exhibits an average EC50 against LAI of 0.7 +/-0.4 nM.

Name

Type

Language

FOSTEMSAVIR

Official Name

English

FOSTEMSAVIR [INN]

Common Name

English

BMS-663068

Code

English

(3-((4-BENZOYLPIPERAZIN-1-YL)-OXOACETYL)-4-METHOXY- 7-(3-METHYL-1H-1,2,4-TRIAZOL-1-YL)-1H-PYRROLO(2,3-C)PYRIDIN- 1-YL)METHYL DIHYDROGEN PHOSPHATE

Systematic Name

English

FOSTEMSAVIR [USAN]

Common Name

English

PIPERAZINE, 1-BENZOYL-4-((4-METHOXY-7-(3-METHYL-1H-1,2,4-TRIAZOL-1-YL)-1-((PHOSPHONOOXY)METHYL)-1H-PYRROLO(2,3-C)PYRIDIN-3-YL)OXOACETYL)-

Systematic Name

English

FOSTEMSAVIR [WHO-DD]

Common Name

English

BMS-663068 FREE ACID

Common Name

English

Code System Code Type Description

PUBCHEM

11319217